Cramer: Keep an Eye on Vertex's Non-Opioid Pain Drug and Lilly's Potential Blockbuster Diabetes Drug

CNBC's Jim Cramer suggested investors watch Vertex Pharmaceuticals, which is developing a non-opioid pain drug called VX-548. He says it could be a huge market opportunity.

Vertex makes most revenue from its cystic fibrosis drug Trikafta, but has late-stage trials underway for VX-548 to create a new class of non-addictive pain meds.

Results from late-stage studies of VX-548 expected within the year. Analysts say its potential is underappreciated.

Cramer's Charitable Trust owns Eli Lilly stock, partly due to its drug Mounjaro for diabetes and obesity. He says it could become the best-selling drug ever.

Cramer's Charitable Trust portfolio includes Vertex, Eli Lilly and other stocks. Mounjaro expected to expand into obesity treatment by year-end.